Merck's Promising Early Alzheimer's Data Can't Quell Efficacy Concerns

 
• By Lucie Ellis-Taitt
Peptid
Will Merck's BACE inhibitor be the first new Alzheimer's drug to market in over a decade? • Source: Shutterstock/Juan Gaertner

More from Neurological

More from Therapeutic Category